Theravance Biopharma TBPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.93M+63.7% | $61.02M+493% | $3.62M+128% | $54.84M+432% | -$13.58M-16.4% | ||
| $381K-7.7% | $399K-5.5% | $405K-5.6% | $409K-4.2% | $413K-4.4% | ||
| $4.5M-7.6% | $4.48M-23.1% | $4.58M-7.8% | $4.54M-15.5% | $4.88M-6.7% | ||
| -$3M-61.9% | —— | —— | -$10.69M-1,806% | -$1.85M-261% | ||
| -$1.47M-984% | $355K-54.9% | $538K+345% | -$733K— | $166K-9.8% | ||
| -$4.87M-221% | —— | $3.61M— | $3.19M— | -$1.51M+55.4% | ||
| -$1.03M-211% | —— | $413K+271% | $1.25M+965% | -$330K-123% | ||
| -$69K-201% | —— | —— | $1K— | $68K+74.4% | ||
| -$42K-208% | $0— | $22K— | $34K— | $39K— | ||
| $1.06M+9.3% | $1.11M+5.1% | $1M-11.2% | $940K-16.9% | $966K-12.3% | ||
| -$2.2M-32.2% | -$1.89M-139% | -$1.86M-10.8% | -$1.7M-36.8% | -$1.66M-32.5% | ||
| $73.28M+70.3% | —— | —— | $208.07M+4,813% | $43.04M+4,311% | ||
| $43.41M+2,106% | $64.93M+72.1% | $124.75M+178% | $56.57M+81.1% | $1.97M-92.7% | ||
| $96M+194% | $65.53M+63.6% | $24.5M-10.9% | $20.35M-27.9% | $32.6M-25.9% | ||
| $52.59M+71.7% | $0-100% | -$100.25M-476% | -$36.26M— | $30.63M+79.9% | ||
| $241K+1,105% | —— | —— | —— | $20K— | ||
| $5.82M+566% | $1.98M+275% | $678K+70.8% | $503K+8.6% | $874K-31.2% | ||
| -$5.58M-553% | -$1.49M-308% | -$400K-7.5% | -$503K-1,043% | -$854K+50.2% | ||
| $120.3M+65.2% | —— | —— | $171.31M— | $72.82M+410% | ||
| -$351K-8,875% | $6.21M+6,302% | $12.77M— | $8.9M+42,286% | $4K+144% | ||
| $602K+84.1% | $1.31M+67.9% | $771K-3.1% | $422K-27.1% | $327K-7.6% | ||
| -$2.2M-32.2% | -$1.89M-139% | -$1.86M-10.8% | -$1.7M-36.8% | -$1.66M-32.5% | ||
| -$69K-201% | —— | —— | $1K— | $68K+74.4% | ||
| -$1.03M-211% | —— | $413K+271% | $1.25M+965% | -$330K-123% | ||
| —— | —— | —— | —— | -$73K-252% | ||
| -$1.67M-1,026% | $814K+123% | $1.18M— | $1.52M+218% | -$148K+96.3% | ||
| -$50M0.0% | —— | —— | —— | -$50M— | ||
| -$29.95M-870% | $27.27M+1,610% | -$3.65M-243% | $6.57M+1,899% | -$3.09M-9.9% | ||
| -$314K-848% | $28K-61.6% | —— | $3K-99.6% | $42K+124% | ||
| —— | $582K-9.5% | $573K-9.0% | $663K+3.0% | $643K+2.2% | ||
| $1.06M+9.3% | $1.11M+5.1% | $1M-11.2% | $940K-16.9% | $966K-12.3% | ||
| $381K-7.7% | $399K-5.5% | $405K-5.6% | $409K-4.2% | $413K-4.4% | ||
| -$42K-208% | $0— | $22K— | $34K— | $39K— | ||
| $1.47M+14.7% | $6.52M+79.1% | $1.36M-46.8% | $1.32M-31.7% | $1.29M-27.8% | ||
| $96M+194% | $65.53M+63.6% | $24.5M-10.9% | $20.35M-27.9% | $32.6M-25.9% | ||
| -$2.2M-32.2% | -$1.89M-139% | -$1.86M-10.8% | -$1.7M-36.8% | -$1.66M-32.5% | ||
| —— | —— | —— | —— | —— | ||
| -$351K-8,875% | $6.21M+6,302% | $12.77M— | $8.9M+42,286% | $4K+144% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Theravance Biopharma generate?
- Theravance Biopharma (TBPH) generated $323.5M in operating cash flow over the trailing twelve months.
- Where does Theravance Biopharma's cash flow data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
